Skip to main content
NovartisPartnership ended

BioArctic collaborator Novartis terminates agreement

Source: Autobound Signal API · 77 signals tracked for Novartis · updated

Get Novartis' live signals in Claude or ChatGPT, or by API

AskWhat changed at Novartis this week? Use Autobound signals for novartis.com.

What happened

Novartis Pharma AG decided to terminate its Option, Collaboration and License Agreement with BioArctic.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

STOCKHOLM, Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Novartis proprietary antibody. The termination is the result of a Novartis decision to discontinue the program, unrelated to BioArctic's BrainTransporter technology. BioArctic will retain the full USD 30 million upfront payment and, as a result of the termination, will recognize the remaining unrecognized portion as revenue in 2026. BioArctic's BrainTransporter technology facilitates the passage of drugs into the brain using the transferrin receptor (TfR). It can be used in a multitude of different therapy areas for delivery of biologics and other modalities to the brain. To date, BioArctic has entered into five collaboration agreements with partners using the BrainTransporter technology. --- This is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on November 2, 2026, at 9:30 pm CET. For further information, please contact: Oskar Bosson, Chief...

Keep reading with a free account

The rest of this article, and every signal for Novartis, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership ended

What this signalsAn ended partnership often leaves a gap another vendor can fill.

Takes effect
Nov 2, 2026
Location
Stockholm, Stockholm, Sweden

Companies

  • BioArctic ABPartnerbioarctic.com

More partnership ended signals at other companies

The full record

From the Signal API record

Extraction

Confidence
95%
Detected
Nov 2, 2026
signal_type
news
signal_subtype
ends_partnership_with

Use this data

Get every partnership ended signal for Novartis and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novartis this week?”

  2. Send it to your own tools

    The Signal API returns partnership ended signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/b42b8b3b-2c76-ea2f-b0ed-bcc4c8fa05ab returns this record as JSON. POST /v1/companies/enrich returns every signal for novartis.com.

{
  "signal_id": "b42b8b3b-2c76-ea2f-b0ed-bcc4c8fa05ab",
  "signal_type": "news",
  "signal_subtype": "ends_partnership_with",
  "detected_at": "2026-11-02T21:14:00+00:00",
  "company": {
    "name": "Novartis",
    "domain": "novartis.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/bioarctic-collaborator-novartis-terminates-agreement-302926959.html",
    "title": "BioArctic collaborator Novartis terminates agreement",
    "excerpt": "STOCKHOLM , Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Novartis proprietary antibody. The termination is the result of a Novartis decision to discontinue the program, unrelated to BioArctic's BrainTransporter technology. BioArctic will retain the full USD 30 million upfront payment and, as a result of the termination, will recognize the remaining unrecognized portion as revenue in 2026. BioArctic's BrainTransporter technology facilitates the passage of drugs into the brain using the transferrin receptor (TfR). It can be used in a multitude of different therapy areas for delivery of biologics and other modalities to the brain. To date, BioArctic has entered into five collaboration agreements with partners using the BrainTransporter technology. --- This is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on November 2, 2026, at 9:30 pm CET. For further information, please contact: Oskar Bosson, Chief...",
    "summary": "Novartis Pharma AG decided to terminate its Option, Collaboration and License Agreement with BioArctic.",
    "location": "Stockholm, Sweden",
    "planning": false,
    "confidence": 0.95,
    "published_at": "2026-11-02T21:14:00Z",
    "location_data": [
      {
        "city": "Stockholm",
        "state": "Stockholm",
        "region": "Northern Europe",
        "country": "Sweden",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-02",
    "article_sentence": "BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Novartis proprietary antibody.",
    "related_company_name": "BioArctic AB",
    "related_company_domain": "bioarctic.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.